PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCaspofungin
Cancidas, Cancidas (previously caspofungin msd)(caspofungin)
Cancidas, Caspofungin (caspofungin) is a small molecule pharmaceutical. Caspofungin was first approved as Cancidas on 2001-01-26. It is used to treat aspergillosis, candidemia, and mycoses in the USA. It has been approved in Europe to treat aspergillosis and candidiasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Caspofungin (discontinued: Cancidas, Caspofungin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caspofungin acetate
Tradename
Company
Number
Date
Products
CASPOFUNGIN ACETATEFresenius KabiN-206110 RX2016-12-30
2 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cancidasNew Drug Application2024-10-11
caspofungin acetateANDA2025-10-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
candidemiaEFO_1001282D058387—
mycoses—D009181B35-B49
aspergillosisEFO_0007157D001228B44
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Caspofungin Acetate, Caspofungin Acetate, Fresenius Kabi Usa
96364072032-12-21DP
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX04: Caspofungin
HCPCS
Code
Description
J0637
Injection, caspofungin acetate, 5 mg
Clinical
Clinical Trials
89 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B49—10143835
CandidiasisD002177—B37—581721
Invasive candidiasisD058365EFO_1001283B37—562215
Invasive fungal infectionsD000072742———241714
CandidemiaD058387EFO_1001282——161412
AspergillosisD001228EFO_0007157B4415—2411
Invasive pulmonary aspergillosisD055744—B44.013—216
Critical illnessD016638—————145
Pneumocystis pneumoniaD011020EFO_0007448B59111125
Liver transplantationD016031EFO_0010682——111—3
Show 13 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——34—916
NeutropeniaD009503—D70—13—37
FungemiaD016469—B49—24——6
LeukemiaD007938—C95132—16
Myeloid leukemia acuteD015470—C92.0123——5
SepsisD018805EFO_0001420A41.9—12—14
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0—12—14
FeverD005334—R50.9—11—24
NeoplasmsD009369—C80—21——3
NeuroblastomaD009447EFO_0000621——11—13
Show 52 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD003141———1——23
Hiv infectionsD015658EFO_0000764B20—1——23
Hematopoietic stem cell transplantationD018380———2———2
AgranulocytosisD000380HP_0012234D70—1———1
Intestinal perforationD007416EFO_1000987P78.0—1———1
Myeloid leukemiaD007951—C9211———1
Myeloproliferative disordersD009196—D47.1—1———1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.2—1———1
Neutrophilic leukemia chronicD015467—D47.1—1———1
Ataxia telangiectasiaD001260Orphanet_100G11.3—1———1
Show 5 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoalbuminemiaD034141——————11
Hepatocellular carcinomaD006528—C22.0————11
Respiratory insufficiencyD012131—J96.9————11
ShockD012769—R57.1————11
FusariosisD060585EFO_1001795—————11
Febrile neutropeniaD064147——————11
HyperthermiaD000084462——————11
RecurrenceD012008——————11
SarcomaD012509——————11
LymphomaD008223—C85.9————11
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCaspofungin
INNcaspofungin
Description
Caspofungin (INN; brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc.. It is a member of a class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall.
Classification
Small molecule
Drug classantifungal antibiotics (undefined group)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
Identifiers
PDB—
CAS-ID162808-62-0
RxCUI—
ChEMBL IDCHEMBL499808
ChEBI ID474180
PubChem CID16119814
DrugBankDB00520
UNII IDF0XDI6ZL63 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cancidas – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,583 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,868 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use